© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Melatonin Implicated in 11K ED Visits for Infants, Children Over 4 Years: MMWR
March 11, 2024
Melatonin products, particularly flavored gummies and tablets, were documented in 7 out of 10 ED visits for unsupervised medication exposure in children aged ≤5 years.
Semaglutide 2.4 mg (Wegovy) Wins Expanded Indication to Include Reduced Risk of MACE
March 08, 2024
The label expansion for semaglutide, based on the SELECT trial, includes data showing reduced risk of CV death of 15% and of death from any cause of 19%.
Underrepresentation of Individuals with CKD in CV Medication Trials Found Persistent Over 2 Decades
March 08, 2024
Authors: Exclusion of people with CKD from CV medication trials has left significant gaps in understanding the effectiveness of these drugs in a highly vulnerable population.
Novo Nordisk Shares Early Findings for Novel Oral Antiobesity Agent
March 07, 2024
The novel unimolecular pill amycretin combines a GLP-1 and an amylin agonist and led to weight loss of 13% at 12 weeks in a phase 1 trial that just concluded, the company said.
In Pregnant Women with T1D, Greater Time in Range Reduces Adverse Maternal, Neonatal Outcomes
March 07, 2024
Higher time in optimal glycemic range was associated with reduced risk for preeclampsia and for birth weight larger than gestational age, new research found.
Real-World Studies Show Significant HbA1c Reductions with GLP-1 RA and Freestyle Libre CGM Used Together
March 06, 2024
One study showed a significant 1.5% decrease in HbA1c 6 months after participants taking a GLP-1 RA started using the Freestyle Libre system.
FDA Clears First-Ever OTC Glucose Sensor: Dexcom Stelo Glucose Biosensor System
March 06, 2024
The Dexcom system is for adults over the age of 18 years who do not use insulin, such as individuals with T2D who use oral medications, a US population of 25 million.
Zilebesiran Reduces Uncontrolled Hypertension as Addition to Standard of Care in Phase 2 KARDIA-2 Trial
March 05, 2024
Topline KARDIA-2 findings showed zilebesiran led to clinically and statistically significant reductions in SBP on top of either a diuretic, CCB, or ARB.
Semaglutide Reduces CKD-Related Events by 24% in Population with T2D and CKD: FLOW Findings Announced
March 05, 2024
Semaglutide 1.0 mg was superior to placebo across the FLOW trial's 5-part primary endpoint with both CKD and CVD components contributing to risk reduction, said Novo Nordisk.
Rapid Progression of CKD Can Be Detected Early Using Simple Markers in Primary Care
March 04, 2024
The 3-year risk of rapid progression from CKD stage G3 was 15% in a large Danish population. Study authors identified accessible key risk factors to aid early detection.